

THIS IS PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



# UNIHEALTH CONSULTANCY LIMITED



(Please scan the QR code to view the Prospectus)

Our company was originally incorporated as "Unihealth Consultancy Private Limited" on February 26, 2010 as a private limited company under the provisions of the Companies Act, 1956 pursuant to Certificate of Incorporation issued by RoC, Mumbai, Maharashtra. The Company was converted into a public limited company pursuant to shareholders resolution passed at the General Meeting of our Company held on December 19, 2022 and the name of our Company was changed to "Unihealth Consultancy Limited" and a Fresh Certificate of Incorporation dated April 26, 2023 was issued by RoC, Mumbai. The Corporate Identification Number of our Company is U85100MH2010PLC200491. For details of incorporation, change of name and registered office of our Company, please refer to chapter titled "General Information" and "History and Certain Corporate Matters" beginning on page 56 and 135 respectively of this Prospectus.

Registered office: H-13 & H-14, Everest, 9th Floor, 156, Tardeo Road, Mumbai- 400034, Maharashtra, India. | Tel: 022 2354 4625; E-mail: [cs@unihealthonline.com](mailto:cs@unihealthonline.com); Website: [www.unihealthonline.com](http://www.unihealthonline.com)  
Contact Person: Prajakta Bhor, Company Secretary and Compliance Officer | Corporate Identity Number: U85100MH2010PLC200491

**OUR PROMOTERS: DR. AKSHAY PARMAR AND DR. ANURAG SHAH**

**THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE ("NSE EMERGE")**

Our Company has filed the Prospectus dated September 14, 2023, with the Registrar of Companies, Mumbai. The Equity Shares are proposed to be listed on the Emerge Platform of National Stock Exchange of India Limited ("NSE EMERGE") and the trading is expected to commence on September 21, 2023.

## BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF 42,84,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF UNIHEALTH CONSULTANCY LIMITED ("COMPANY") FOR CASH AT A PRICE OF ₹ 132 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 122 PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹ 5,654.88 LAKHS OF WHICH UP TO 2,16,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH FOR CASH AT A PRICE OF ₹ 132 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 122 PER EQUITY SHARE AGGREGATING TO ₹ 285.12 WAS RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 40,68,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT A PRICE OF ₹ 132 PER EQUITY SHARE AGGREGATING TO ₹ 5,369.76 IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 27.82% AND 26.42% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF EQUITY SHARES IS ₹ 10 EACH. THE ISSUE PRICE IS 13.2 TIMES THE FACE VALUE OF THE EQUITY SHARES.

**ISSUE PRICE: ₹ 132 PER EQUITY SHARE OF FACE VALUE OF ₹ 10 EACH  
THE ISSUE PRICE IS 13.2 TIMES OF THE FACE VALUE OF EQUITY SHARES**

## RISK TO INVESTORS

a. The average cost of acquisition of shares of our promoters are as follows:

Sr. No.	Name of Promoters	No. of Equity Shares acquired	Average Cost of acquisition Price (in ₹ per equity share)
1.	Dr. Anurag Shah	50,00,000	1.25
2.	Dr. Akshay Parmar	41,80,000	0.75

#As certified by our Statutory and Peer review Auditors, by way of their certificate dated August 28, 2023.

b. Weighted Average Cost of Acquisition for all Equity Shares transacted in one year, eighteen months and three years preceding the date of the Red Herring Prospectus by all the shareholders:

Period	Weighted Average Cost of Acquisition (in ₹)	Upper end of the Price band (₹ 132 is 'X' times the Weighted Average Cost of Acquisition)	Range of acquisition price: Lowest Price - Highest Price (in ₹)
Last 1 year	26.49	4.98	0-131.25
Last 18 months	26.49	4.98	0-131.25
Last 3 years	26.50	4.98	0-137.5

#As certified by our Statutory and Peer review Auditors, by way of their certificate dated September 02, 2023.

c. The weighted average cost of acquisition compared to floor price and cap price.

Past Transactions	Weighted average cost of acquisition (₹)	Floor Price ₹ 126	Cap Price ₹ 132
WACA of Primary Issue (except for bonus issue)	131.25	0.96	1.01
WACA for Secondary sale/ acquisitions not exceeding 5% of the pre issue capital	Nil	Nil	Nil

d. BRLM associated with the Issue has handled 12 public issues in the past three years. Below are the details:

Particulars	Number of issue/ Offer handled	Issue closed below the issue price on listing date
Main Board	5	-
SME	7	1

e. The Price/Earnings ratio based on diluted EPS for Fiscal 2023 for our Company at the upper end of the Price Band is 19.02 times.

f. Weighted Average Return on Net Worth for fiscals 2023, 2022 and 2021 is 30.36%.

g. Our Business are interconnected, and any deterioration in one of our group businesses can potentially have adverse effects on the overall performance of our Company.

h. We face risks associated with providing project management consultancy services to the hospitals.

## BID/ISSUE PERIOD

**ANCHOR INVESTOR BID/ ISSUE PERIOD THURSDAY, SEPTEMBER 07, 2023**

**BID/ISSUE OPENED ON FRIDAY, SEPTEMBER 08, 2023**

**BID/ISSUE CLOSED ON TUESDAY, SEPTEMBER 12, 2023**

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company in consultation with the BRLM may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"). One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) ("Net QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders, other than Anchor Investors, are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" on page 246.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of the Issue, the Designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on or about September 21, 2023\*.

\*Subject to the receipt of listing and trading approval from NSE Emerge Platform.

The bidding period for Anchor Investors opened on Thursday, September 07, 2023, and closed on Thursday, September 07, 2023. The Company received 6 Anchor Investor Bid Cum Application forms for 13,75,000 Equity Shares at ₹ 132. The Anchor subscribed by 1.13 times, the final allocation to Anchor Investors made for 12,18,000 Equity Shares at ₹ 132 per Equity share aggregating to ₹ 16,07,76,000/-

Details of applications received in the Issue from Retail Investors, Non-Institutional Investors and QIBs and Anchor Investors are as under (before technical rejections):

Sr. No.	Category	Number of Applications Received	Number of Shares Bid for	Equity shares reserved as per Prospectus	No. of times subscribed	Amount of total bids (₹)
1	Market Maker	1	2,16,000	2,16,000	1.00	2,85,12,000.00
2	Retail Individual Bidders	35,092	3,50,92,000	14,24,000	26.64	4,63,16,60,000.00
3	Non-Institutional Bidders	2,554	23,17,9000	6,11,000	37.37	3,05,90,64,000.00
4	Qualified Institutional Bidders (excluding Anchor Investors)	13	1,19,47,000	8,15,000	14.66	1,57,70,04,000.00
5	Anchor Investor	6	13,75,000	12,18,000	1.13	16,07,76,000.00
<b>Total</b>		<b>37,666</b>	<b>7,18,09,000</b>	<b>42,84,000</b>	<b>78.16</b>	<b>94,57,01,000.00</b>

### Final Demand:

A Summary of the final demand per NSE as on Bid/Issue closing date at different Bid Price is as under:

Sr. No.	Bid Price	No. of Bids	Shares Applied	Application Amount
1	126	131	1,40,000	1,76,40,000
2	127	9	9,000	11,43,000
3	128	20	21,000	26,88,000
4	129	21	23,000	29,67,000
5	130	63	69,000	89,70,000
6	131	45	53,000	69,43,000
7	132	35,678	6,86,25,000	9,05,85,00,000
8	9,99,999	20,578	205,78,000	2,71,62,96,000
<b>Total</b>	<b>9,99,999</b>	<b>56,545</b>	<b>8,95,18,000</b>	<b>11,81,51,47,000</b>

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange-NSE on September 15, 2023.

### A. Allotment to Market Maker:

The Registrar informed that in this category 1 valid application for 2,16,000 Shares were received against 2,16,000 Equity Shares reserved for this category resulting in subscription of 1.00 time.

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/allotted
2,16,000	1	100.00	2,16,000	100.00	2,16,000	1	2,16,000
<b>Grand Total</b>	<b>1</b>	<b>100.00</b>	<b>2,16,000</b>	<b>100.00</b>	<b>2,16,000</b>	<b>1</b>	<b>2,16,000</b>

### b. Allotment to Retail Individual and Non-Institutional Investors:

The Registrar informed that in Retail & Non-Retail category overall 36,684 valid applications for 5,70,12,000 Equity Shares were received, against total of 20,35,000 Equity Shares (includes 23 applications for 2,03,000 equity shares shifted from QIB Category due to bidding by non-retail individual investors in QIB Category, accordingly these 23 applications were re-categorized to non-retail individual investors Category).

#### \* Retail Individual Investors Category:

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/allotted
1000	34181	100.00	34181000	100.00	1424000	1	1424000
<b>Grand Total</b>	<b>34181</b>	<b>100.00</b>	<b>34181000</b>	<b>100.00</b>	<b>1424000</b>	<b>1</b>	<b>1424000</b>

#### \* Non Institutional Investors category: (Sample)

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/allotted
2000	1769	70.67	3538000	15.49	94683	29	540
3000	163	6.51	489000	2.14	13087	13	163
4000	82	3.27	328000	1.43	8778	9	82
5000	31	1.23	155000	0.67	4148	4	31
6000	26	1.03	156000	0.68	4175	2	13
7000	24	0.95	168000	0.73	4496	1	6
8000	100	3.99	800000	3.5	21409	21	100
9000	29	1.15	261000	1.14	6985	7	29
10000	27	1.07	270000	1.18	7226	7	27
11000	10	0.39	110000	0.48	2944	3	10
12000	14	0.55	168000	0.73	4496	5	14

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/allotted
2000	1769	70.67	3538000	15.49	94683	29	540
3000	163	6.51	489000	2.14	13087	13	163
4000	82	3.27	328000	1.43	8778	9	82
5000	31	1.23	155000	0.67	4148	4	31
6000	26	1.03	156000	0.68	4175	2	13
7000	24	0.95	168000	0.73	4496	1	6
8000	100	3.99	800000	3.5	21409	21	100
9000	29	1.15	261000	1.14	6985	7	29
10000	27	1.07	270000	1.18	7226	7	27
11000	10	0.39	110000	0.48	2944	3	10
12000	14	0.55	168000	0.73	4496	5	14
13000	2	0.07	26000	0.11	696	1	2
14000	2	0.07	28000	0.12	749	1	2
15000	11	0.43	165000	0.72	4416	4	11
16000	6	0.23	96000	0.42	2569	1	2
17000	3	0.11	51000	0.22	1365	1	3
18000	7	0.27	126000	0.55	3372	3	7
19000	5	0.19	95000	0.41	2542	3	5
20000	5	0.19	100000	0.43	2676	3	5
21000	5	0.19	105000	0.45	2810	3	5
22000	5	0.19	110000	0.48	2944	3	5
23000	2	0.07	46000	0.2	1231	1	2
24000	1	0.03	24000	0.1	642	1	1
25000	7	0.27	175000	0.76	4683	5	7
26000	5	0.19	130000	0.56	3479	3	5
27000	2	0.07	54000	0.23	1445	1	2
28000	2	0.07	56000	0.24	1499	1	2
29000	2	0.07	58000	0.25	1552	1	2
30000	3	0.11	90000	0.39	2409	2	3
31000	2	0.07	62000	0.27	1659	1	2
32000	1	0.03	32000	0.14	856	1	1
33000	2	0.07	66000	0.28	1766	1	2
34000	1	0.03	34000	0.14	910	1	1
35000	3	0.11	105000	0.45	2810	1	3
36000	4	0.15	144000	0.63	3854	1	4
37000	2	0.07	74000	0.32	1980	1	2
38000	2	0.07	76000	0.33	2034	1	2
40000	4	0.15	160000	0.7	4282	1	4
41000	8	0.31	328000	1.43	8778	1	8
45000	1	0.03	45000	0.19	1204	1	1
47000	1	0.03	47000	0.2	1258	1	1
48000	1	0.03	48000	0.21	1285	1	1
49000	1	0.03	49000	0.21	1311	1	1
50000	7	0.27	350000	1.53	9367	1	7
60000	2	0.07	120000	0.52	3211	1	2
63000	1	0.03	63000	0.27	1686	1	1
67000	3	0.11	201000	0.88	5379	1	3

Continue From Next Page

# Share sale boom to reach \$30 bn in 2024: JPMorgan

Firm's equity mkt's head sees a couple of \$1 bn-plus IPOs after general elections

BAIJU KALESH & CHIRANJIVI CHAKRABORTY  
18 September

India will see at least \$30 billion raised annually through primary and secondary share sales in 2024 and in the years to come, as companies and their shareholders are more willing to tap the market for funding, according to JPMorgan Chase.

Sales of additional shares in listed companies have surpassed \$10 billion this year, more than the tally for all of 2022, according to data compiled by Bloomberg.

The momentum can sustain into next year and beyond as owners of Indian companies are keen to raise funds for other investments, said Abhinav Bharti, India head of equity capital markets at JPMorgan. Demand from local asset managers as well as foreign investors is also driving share sales, he added. "In block trades, every year now you can average \$10 billion from 2024 onwards," Bharti said in an interview in Mumbai. "I can see the building blocks of India becoming a market that can every year raise more than \$30



ILLUSTRATION: BINAY SINHA

## THE GOOD, THE BAD AND THE...

■ Sales of additional shares in listed firms have surpassed \$10 bn in '23, more than the tally for all of '22

■ Companies have raised over \$5.2 bn through IPOs so far in 2023...

...This number is down from billion from primary and secondary sales for corporates."

"JPMorgan is the top manager of equity and rights offerings in India in the first eight months of 2023, according to data compiled by Bloomberg League Tables. The American

\$5.5 billion for the same period in 2022

■ Strong corporate earnings and robust economic growth are drawing investors

■ China's currency has plunged amid concerns over the nation's precarious economic outlook and geopolitical tensions

bank has a market share of nearly 15 per cent, followed by Kotak Mahindra Bank, which has an 11 per cent share of the market.

In contrast to block trades, the initial public offering (IPO) activity has slowed down sig-

nificantly this year, tracking a global slump in dealmaking. Companies have raised about \$3.2 billion through first-time share sales so far in 2023, down from \$5.5 billion for the same period last year, data compiled by Bloomberg shows.

A couple of \$1 billion-plus IPOs could return after the general elections between April and May, Bharti said. The banker expects bigger IPOs to come from sectors such as consumer, technology and financial services.

Strong corporate earnings and robust economic growth are drawing investors even as they flee other Asian emerging markets.

China's currency has plunged amid concerns over the once fast-growing nation's precarious economic outlook and geopolitical tensions.

"Because of recent softness in Chinese economic data, a lot of these global EM fund managers are underweight on China and now where you go and deploy that extra capital, you must have a counterweight as well," Bharti said while adding that, "India is benefiting from that." **BLOOMBERG**

## THE COMPASS

# Tata Steel green investment positive for UK operations

Once operational in full capacity, the project would reduce costs by \$150-170 per tonne

DEVANGSHU DATTA

Tata Steel UK is reformatting its operations in Port Talbot by investing in a 1.25 billion pounds electric arc furnace facility with the UK Government contributing 500 million pounds. The project will take around 36 months to complete assuming regulatory clearances come through. The facility will use scrap and be classified as green since it will use renewable power and cut carbon emissions considerably. The company will also have to consult unions and other stakeholders during this process and that could take up to two months.

Despite the upfront investment which will come from internal accruals, the project should eventually add to earnings and be more sustainable than the current facility which is coming to the end of its operational lifespan. Apart from the furnace, the project includes

enhancement of two casters, a hot steel strip mill, and the consolidation of a cold rolling mill.

Once operational at full capacity, costs would reduce by \$150-170 per tonne compared to the alternative blast furnace process. The scrap would be sourced from within the UK which should make it cost-effective. The UK is developing renewable power capacity which will be among the cheapest sources in Europe.

Emission should reduce from the current 2.16 tonnes of carbon dioxide (CO2) to around 0.4 tonnes of CO2 per tonne of steel. The other key advantage is that

this would sidestep likely taxes that could be imposed on higher emission blast furnace processes.

The UK consumes 10 million tonnes per annum of steel. TATA UK holds a 50 per cent market share in the auto industry, 43 per cent in construction, and 62 per cent in packaging. Best guess is that the return on investment for the project could be around 15-16 per cent.


TATA has an outstanding loan of around \$1.3 billion for its European operations including working capital requirements in the UK and the Netherlands, as well as legacy acquisitions and leases.

The project aims to restructure Tata Steel's balance sheet, potentially eliminating cash losses in UK operations and recognising non-cash impairments of legacy

investments. During the transition period and project phase, Tata Steel UK would ensure uninterrupted supply of products to fulfil commitments and import steel substrate to feed downstream units. The company would also invest about 20 million pounds over the next four years to set up two additional Centres of Innovation & Technology at the Henry Royce Institute at Manchester (for advanced materials research) and at Imperial College London (for research in Sustainable Design & Manufacturing).

The project will help preserve employment, but some of Tata Steel UK's 8,000 employees may need to be rationalised which is why discussion with the unions is necessary. If a substantial number of jobs are lost - up to 3,000 according to some estimates - Tata Steel will have to pay to settle one-time restructuring charges.


More details will be available when the company does its annual post-Q2FY24 results. The initial reaction from analysts is positive but the stock has not moved much.



Source: Exchanges  
Compiled by BS Research Bureau

# Inflows into gold ETF hit 16-month high at ₹1,028 cr in August

## RAISING THE BAR



Source: Amfi  
Compiled by BS Research Bureau

PRESS TRUST OF INDIA  
New Delhi, 18 September

Gold exchange-traded funds (ETFs) attracted ₹1,028 crore in August, making it the highest inflow in 16 months, amid continued hikes in interest rates in the US, which led to a slowing down in growth rate there.

With this, the year-to-date inflow in the category has reached

more than ₹1,400 crore, data with the Association of Mutual Funds in India (AMFI) showed.

Apart from inflow, the asset base of Gold ETFs and investors' account or folio numbers increased in the period under review.

According to data, gold-linked ETFs have seen an inflow of ₹1,028 crore in August. This came following an inflow of ₹456 crore in the segment in July.

Before that, Gold ETF saw inflow to the tune of ₹298 crore during the April-June period after three quarters of consecutive outflow. The category saw a withdrawal of ₹1,243 crore in the March quarter, ₹320 crore in the December quarter, and ₹165 crore in the September quarter.

The month of August witnessed the highest monthly inflow into Gold ETFs since April 2022 when

the category attracted ₹1,100 crore on the back of the Russia-Ukraine war.

Flows into Gold ETFs have been subdued since then as the US Federal Reserve (Fed) embarked on its tightening cycle.

As the end of the Fed's tightening cycle is now coming close, prospects for gold are looking good. "The metal has held its ground despite US yields and the US dollar

being on an upward trajectory lately. A potential US recession, central bank gold buying, geopolitical tensions, rising US debt levels are all supporting interest in the precious metal," Ghazal Jain, Fund Manager - Alternative Investments at Quantum Mutual Fund, said.

Moreover, gold prices in recent times have come off from its all-time high levels, thereby providing some buying opportunity.

Continue From Previous Page

No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	Proportionate shares available	Ratio of allottees to applicants	Total No. of shares allocated/allotted
67000						2	3
68000	2	0.07	136000	0.59	3640	1	1
75000	6	0.23	450000	1.97	12043	1	1
76000	8	0.31	608000	2.66	16271	1	1
77000	2	0.07	154000	0.67	4121	1	1
82000	1	0.03	82000	0.35	2194	1	1
83000	1	0.03	83000	0.36	2221	1	1
84000	2	0.07	168000	0.73	4496	1	1
91000	1	0.03	91000	0.39	2435	1	1
95000	1	0.03	95000	0.41	2542	1	1
99000	1	0.03	99000	0.43	2649	1	1
100000	1	0.03	100000	0.43	2676	1	1
115000	1	0.03	115000	0.5	3078	1	1
122000	2	0.07	244000	1.06	6530	1	1
152000	2	0.07	304000	1.33	8136	1	1
153000	2	0.07	306000	1.34	8189	1	1
163000	1	0.03	163000	0.71	4362	1	1
170000	1	0.03	170000	0.74	4550	1	1
178000	1	0.03	178000	0.77	4764	1	1
237000	1	0.03	237000	1.03	6343	1	1
252000	1	0.03	252000	1.1	6744	1	1
284000	1	0.03	284000	1.24	7600	1	1
333000	1	0.03	333000	1.45	8912	1	1
335000	1	0.03	335000	1.46	8965	1	1
392000	1	0.03	392000	1.71	10491	1	1
1136000	1	0.03	1136000	4.97	30401	1	1
1819000	1	0.03	1819000	7.96	48880	1	1
<b>TOTAL</b>	<b>2503</b>	<b>100</b>	<b>22831000</b>	<b>100</b>	<b>611000</b>		<b>611000</b>

### C. Allotment to Qualified Institutional Buyers (QIBs):

Allotment to QIBs who have Bid at the Issue Price of ₹ 132 per Equity Share or above, has been done on a proportionate basis in consultation with NSE. The Registrar confirmed that there were 36 applications for 1,21,50,000 Equity Shares bid under QIB category as per the bid book. Of these, there are 23 applications for 2,03,00,000 Equity Shares bid by non-retail investors in the QIB Category. Accordingly, these 23 applications for 2,03,00,000 were re-categorized to non-retail investors Category. Under the QIB portion, 5% was reserved for Mutual Funds, however, no mutual funds applied in the issue. The Registrar confirmed that there were 13 valid applications for 1,19,47,000 Equity Shares bid under QIB category as per the bid book received from NSE.

Category	Fis	Banks	MFs	ICs	NBFCs	AIF	FPI	Others	TOTAL
QIB	35,000	1,95,000	-	29,000	-	14,000	2,70,000	2,72,000	8,15,000

### d. Allotment to Anchor Investors:

The Company, in consultation with BRLM, have allocated 12,18,00,000 Equity Shares at ₹ 132 per Equity share aggregating to ₹ 16,07,76,00,000 - in accordance with SEBI ICDR Regulations. This represents 60% of the QIB Portion:

Category	Fis	Banks	MFs	ICs	NBFCs	AIF	FPI	Others	TOTAL
Anchor	-	-	-	-	-	-	6,86,000	5,32,000	12,18,000

The Board Meeting of our Company on September 15, 2023 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being NSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum-refund information are being dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self-Certified Syndicate Banks for unblocking of funds, transfer to Public Issue Account have been issued on September 15, 2023 and payment to Non-Syndicate brokers have been issued on September 15, 2023. In case the same is not received within four days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares Allotted to the successful Allottees are being credited to the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from NSE, and the trading is expected to commence on or about September 21, 2023. All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

### INVESTORS PLEASE NOTE

The details of the Allotment made have been hosted on the website of Registrar to the Issue, Bigshare Services Private Limited at [www.bigshareonline.com](http://www.bigshareonline.com). All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole applicant. Serial number of the ASBA form, number of Equity Shares bid for, name of the Member of the Syndicate, place where the bid was submitted and payment details at the address given below.

### NOTICE TO INVESTORS

#### Potential Investors may note the following:

We have provided Comparison of financial KPIs of our Company and our listed peer for the Financial years ended March 31, 2023, March 31, 2022 and March 31, 2021 in Red Herring Prospectus dated September 01, 2023, under chapter "Basis for Issue Price" on page 94 in which inadvertently mentioned the financial years as March 31 2022, March 31 2021 and March 31, 2020 of our peer 'KMC Speciality Hospitals (India) Limited' and in clarification for same we request investors to read the same as March 31, 2023, March 31, 2022 and March 31, 2021 only. This notice is to bring to the attention of our potential investors that the figures are correct and fair as per the Financial Year 2023, 2022 and 2021. We have rectified the same in the prospectus under chapter "Basis for Issue Price" on page 94.

#### BIGSHARE SERVICES PRIVATE LIMITED

S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400 093, Maharashtra, India  
 Telephone: 022 6263 8200  
 Facsimile: 022 6263 8209  
 Email: [ipo@bigshareonline.com](mailto:ipo@bigshareonline.com)  
 Investor Grievance Email: [investor@bigshareonline.com](mailto:investor@bigshareonline.com)  
 Contact Person: Babu Rathelal C.  
 Website: [www.bigshareonline.com](http://www.bigshareonline.com)  
 SEBI Registration Number: INR000001385  
 CIN: U99999MH1994PTC076534

Place: Mumbai

Date: September 18, 2023

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF UNHEALTH CONSULTANCY LIMITED.

Unhealth Consultancy Limited has filed the Prospectus dated September 14, 2023 with Registrar of Companies, Mumbai. The Prospectus shall be available on the website of the SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), the website of the BRLM to the Issue at [www.unhealthonline.com](http://www.unhealthonline.com) and website of NSE at [www.nseindia.com](http://www.nseindia.com). Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 30 of the Prospectus.

The Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered may not be offered in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable U.S. state securities laws. There will be no public offering in the United States and the securities being offered in this announcement are not being offered or sold in the United States.

For Unhealth Consultancy Limited  
On Behalf of the Board of Directors



Companies,  
Insight Out

Companies, Monday to Saturday

To book your copy,  
sms reachbs to 57575 or email order@bsmail.in

Business Standard  
Insight Out